Target type: biologicalprocess
The chemical reactions and pathways resulting in the formation of nicotinamide adenine dinucleotide (NAD) from the vitamin precursor nicotinamide riboside. [PMID:17482543]
NAD biosynthesis via nicotinamide riboside salvage pathway is a critical metabolic route for generating nicotinamide adenine dinucleotide (NAD+), a vital coenzyme involved in numerous cellular processes, including energy production (via oxidative phosphorylation), DNA repair, and signal transduction. This pathway utilizes nicotinamide riboside (NR), a naturally occurring NAD+ precursor, as its substrate.
The pathway commences with the uptake of NR from the extracellular environment or intracellular sources. NR is then transported into the cytoplasm, where it encounters the enzyme nicotinamide riboside kinase (NRK). NRK catalyzes the phosphorylation of NR to nicotinamide mononucleotide (NMN), using ATP as a phosphate donor.
NMN serves as the substrate for the enzyme nicotinamide mononucleotide adenylyltransferase (NMNAT), which catalyzes the final step in NAD+ biosynthesis from NR. NMNAT utilizes ATP to adenylylate NMN, yielding NAD+. This reaction occurs predominantly in the nucleus, where NAD+ is required for various nuclear functions.
The nicotinamide riboside salvage pathway is highly efficient and provides a significant contribution to the cellular NAD+ pool. Notably, NR is readily absorbed from the diet and can be synthesized in various tissues, contributing to the pathway's importance in maintaining cellular NAD+ homeostasis.
In addition to its role in NAD+ biosynthesis, the nicotinamide riboside salvage pathway also plays a crucial role in regulating cellular NAD+ levels. The pathway is tightly regulated by the availability of NR, the activity of NRK and NMNAT, and the cellular NAD+ demand.
Overall, the nicotinamide riboside salvage pathway is a fundamental metabolic process that ensures adequate NAD+ levels for various cellular functions. This pathway is essential for maintaining cellular health and has gained significant attention for its potential therapeutic implications in various diseases, including aging and neurodegenerative disorders.'
"
Protein | Definition | Taxonomy |
---|---|---|
Protein mono-ADP-ribosyltransferase PARP16 | A protein mono-ADP-ribosyltransferase PARP16 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q8N5Y8] | Homo sapiens (human) |
Protein mono-ADP-ribosyltransferase PARP9 | A protein mono-ADP-ribosyltransferase PARP9 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q8IXQ6] | Homo sapiens (human) |
Protein mono-ADP-ribosyltransferase PARP10 | A protein mono-ADP-ribosyltransferase PARP10 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q53GL7] | Homo sapiens (human) |
Prostacyclin synthase | A prostacyclin synthase that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q16647] | Homo sapiens (human) |
Nicotinamide phosphoribosyltransferase | A nicotinamide phosphoribosyltransferase that is encoded in the genome of human. [PRO:DNx, UniProtKB:P43490] | Homo sapiens (human) |
Nicotinamide N-methyltransferase | A nicotinamide N-methyltransferase that is encoded in the genome of human. [PRO:DNx, UniProtKB:P40261] | Homo sapiens (human) |
Protein mono-ADP-ribosyltransferase PARP16 | A protein mono-ADP-ribosyltransferase PARP16 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q8N5Y8] | Homo sapiens (human) |
Protein mono-ADP-ribosyltransferase PARP9 | A protein mono-ADP-ribosyltransferase PARP9 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q8IXQ6] | Homo sapiens (human) |
Protein mono-ADP-ribosyltransferase PARP10 | A protein mono-ADP-ribosyltransferase PARP10 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q53GL7] | Homo sapiens (human) |
Prostacyclin synthase | A prostacyclin synthase that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q16647] | Homo sapiens (human) |
Nicotinamide phosphoribosyltransferase | A nicotinamide phosphoribosyltransferase that is encoded in the genome of human. [PRO:DNx, UniProtKB:P43490] | Homo sapiens (human) |
Nicotinamide N-methyltransferase | A nicotinamide N-methyltransferase that is encoded in the genome of human. [PRO:DNx, UniProtKB:P40261] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
benzamide | benzamide : An aromatic amide that consists of benzene bearing a single carboxamido substituent. The parent of the class of benzamides. | benzamides | |
ci 994 | tacedinaline : A benzamide obtained by formal condensation of the carboxy group of 4-acetamidobenzoic acid with one of the amino groups of 1,2-phenylenediamine. An oral cytostatic drug with impressive differential activity against leukemic cells and normal stem-cells. Also used in combination therapy for selected tumors including non-smoll cell lung, pancreatic, breast, and colorectal cancers. tacedinaline: oral cytostatic drug with impressive differential activity against leukemic cells & normal stem-cells | acetamides; benzamides; substituted aniline | antineoplastic agent; EC 3.5.1.98 (histone deacetylase) inhibitor |
diazoxide | diazoxide : A benzothiadiazine that is the S,S-dioxide of 2H-1,2,4-benzothiadiazine which is substituted at position 3 by a methyl group and at position 7 by chlorine. A peripheral vasodilator, it increases the concentration of glucose in the plasma and inhibits the secretion of insulin by the beta- cells of the pancreas. It is used orally in the management of intractable hypoglycaemia and intravenously in the management of hypertensive emergencies. Diazoxide: A benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group. | benzothiadiazine; organochlorine compound; sulfone | antihypertensive agent; beta-adrenergic agonist; bronchodilator agent; cardiotonic drug; diuretic; K-ATP channel agonist; sodium channel blocker; sympathomimetic agent; vasodilator agent |
pj-34 | PJ34 : A member of the class of phenanthridines that is 5,6-dihydrophenanthridine substituted at positions 2 and 6 by (N,N-dimethylglycyl)amino and oxo groups, respectively. It is a potent inhibitor of poly(ADP-ribose) polymerases PARP1 and PARP2 (IC50 of 110 nM and 86 nM, respectively) and exhibits anti-cancer, cardioprotective and neuroprotective properties. | phenanthridines; secondary carboxamide; tertiary amino compound | angiogenesis inhibitor; anti-inflammatory agent; antiatherosclerotic agent; antineoplastic agent; apoptosis inducer; cardioprotective agent; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; neuroprotective agent |
1,2,3,4-tetrahydroisoquinoline | 1,2,3,4-tetrahydroisoquinoline: RN given refers to cpd with locants as specified | isoquinolines | |
quinoline | azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinolines | ||
isoquinoline | azaarene; isoquinolines; mancude organic heterobicyclic parent; ortho-fused heteroarene | ||
6-aminonicotinamide | 6-aminonicotinamide : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of 6-aminonicotinic acid with ammonia. An inhibitor of the NADP(+)-dependent enzyme, 6-phosphogluconate dehydrogenase, it interferes with glycolysis, resulting in ATP depletion and synergizes with DNA-crosslinking chemotherapy drugs, such as cisplatin, in killing cancer cells. 6-Aminonicotinamide: A vitamin antagonist which has teratogenic effects. | aminopyridine; monocarboxylic acid amide; primary amino compound | antimetabolite; EC 1.1.1.44 (NADP(+)-dependent decarboxylating phosphogluconate dehydrogenase) inhibitor; teratogenic agent |
dazoxiben | dazoxiben: RN given refers to parent cpd | ||
dazmegrel | |||
pirmagrel | pirmagrel: structure given in first source | ||
sinefungin | adenosines; non-proteinogenic alpha-amino acid | antifungal agent; antimicrobial agent | |
n'-methyl-2-pyridone-5-carboxamide | N-methyl-6-pyridone-3-carboxamide : A pyridone that is 2-pyridone substituted with a carboxamide group at C-5 and a methyl group at N-1. N'-methyl-2-pyridone-5-carboxamide: structure | methylpyridines; pyridinecarboxamide; pyridone | metabolite; mouse metabolite |
4-Methoxybenzamide | benzamides | ||
3,4-dihydro-5-methyl-1(2h)-isoquinolinone | 3,4-dihydro-5-methyl-1(2H)-isoquinolinone: structure given in first source | isoquinolines | |
chs 828 | aromatic ether | ||
1-oxo-1,2,3,4-tetrahydroisoquinoline | 1-oxo-1,2,3,4-tetrahydroisoquinoline: structure given in first source | ||
n(4)-adenosyl-n(4)-methyl-2,4-diaminobutanoic acid | |||
uk 34787 | UK 34787: RN given refers to parent cpd | ||
s-adenosylhomocysteine | S-adenosyl-L-homocysteine : An organic sulfide that is the S-adenosyl derivative of L-homocysteine. S-Adenosylhomocysteine: 5'-S-(3-Amino-3-carboxypropyl)-5'-thioadenosine. Formed from S-adenosylmethionine after transmethylation reactions. | adenosines; amino acid zwitterion; homocysteine derivative; homocysteines; organic sulfide | cofactor; EC 2.1.1.72 [site-specific DNA-methyltransferase (adenine-specific)] inhibitor; EC 2.1.1.79 (cyclopropane-fatty-acyl-phospholipid synthase) inhibitor; epitope; fundamental metabolite |
thionicotinamide | |||
stf-31 | STF-31: antineoplastic | ||
isbogrel | |||
fk 866 | N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide: inhibits nicotinamide phosphoribosyltransferase; structure in first source | benzamides; N-acylpiperidine | |
rucaparib | AG14447: Poly(ADP-ribose) polymerase inhibitor; structure in first source | azepinoindole; caprolactams; organofluorine compound; secondary amino compound | antineoplastic agent; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor |
latonduine a | latonduine A: structure in first source | ||
veliparib | benzimidazoles | EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor | |
chidamide | benzamides | ||
quinoline-3-carboxamide | quinoline-3-carboxamide: structure in first source | ||
olaparib | cyclopropanes; monofluorobenzenes; N-acylpiperazine; phthalazines | antineoplastic agent; apoptosis inducer; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor | |
niraparib | niraparib : A 2-[4-(piperidin-3-yl)phenyl]-2H-indazole-7-carboxamide that has S-configuration. It is a potent inhibitor of PARP1 and PARP2 (IC50 of 3.8 and 2.1 nM, respectively) and approved as a first-line maintenance treatment for women with advanced ovarian cancer after responding to platinum-based chemotherapy. niraparib: structure in first source | 2-[4-(piperidin-3-yl)phenyl]-2H-indazole-7-carboxamide | antineoplastic agent; apoptosis inducer; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; radiosensitizing agent |
pf 9184 | |||
gne-618 | GNE-618: inhibits nicotinamide phosphoribosyl transferase; structure in first source | ||
g007-lk | G007-LK: potent and specific small-molecule tankyrase inhibitor; structure in first source | ||
gne-617 | GNE-617: inhibits nicotinamide phosphoribosyltransferase; structure in first source | ||
xav939 | XAV939 : A thiopyranopyrimidine in which a 7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine skeleton is substituted at C-4 by a hydroxy group and at C-2 by a para-(trifluoromethyl)phenyl group. XAV939: selectively inhibits beta-catenin-mediated transcription; structure in first source | (trifluoromethyl)benzenes; thiopyranopyrimidine | tankyrase inhibitor |
bmn 673 | talazoparib: inhibits both PARP1 and PARP2; structure in first source |